Note*: This report requires 5-10 business days to complete.
DelveInsight’s “Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Size Forecast-2020” Reports provides an overview of the disease and global market size of the Non-Hodgkin’s Lymphoma (NHL) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Non-Hodgkin’s Lymphoma (NHL) from 2010-2020.Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow).About 72,580 people (40,170 males and 32,410 females) will be diagnosed with NHL. This includes both adults and children. About 20,150 people will die from this cancer (11,520 males and 8,630 females). In general, with modern treatment of patients with NHL, overall survival at 5 years is over 60%. Of patients with aggressive NHL, more than 50% can be cured. The vast majority of relapses occur in the first 2 years after therapy. The risk of late relapse is higher in patients who manifest both indolent and aggressive histology.
Scope
• Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
• It also provides Market size of Non-Hodgkin’s Lymphoma (NHL) for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
'
Table of Contents
• Non-Hodgkin’s Lymphoma (NHL)
• Disease overview:
• Pathophysiology:
• Symptoms of disease:
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• United States
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Non-Hodgkin’s Lymphoma (NHL) Market
• Global Epidemiology of Non-Hodgkin’s Lymphoma (NHL) Forecasted to 2020
• Global Market size (2011-2014)
• Global Forecasted Market size (2015-2020)
• Global Market Size by Geography
• Market size of US (2011-2014)
• Forecasted Market size of US (2015-2020)
• Market size of Europe
• Market size of Germany (2011-2014)
• Forecasted Market size of Germany (2015-2020)
• Market size of United Kingdom (2011-2014)
• Forecasted Market size of United Kingdom (2015-2020)
• Market size of France (2011-2014)
• Forecasted Market size of France (2015-2020)
• Market size of Italy (2011-2014)
• Forecasted Market size of Italy (2015-2020)
• Market size of Spain (2011-2014)
• Forecasted Market size of Spain (2015-2020)
• Market size of Japan (2011-2014)
• Forecasted Market Size of Japan (2015-2020)
• Market size of ROW (2011-2014)
• Forecasted Market size of ROW (2015-2020)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Non-Hodgkin’s Lymphoma (NHL) Drug Sales (USD Millions), (2014-2020)
• Table 6: Global Epidemiology of Non-Hodgkin’s Lymphoma (NHL) (2011-2020)
• Table 7: Non-Hodgkin’s Lymphoma (NHL) Global Market Size (USD Millions), (2011-2014)
• Table 8: Non-Hodgkin’s Lymphoma (NHL) Global Market Size (USD Millions), (2015-2020)
• Table 9: Non-Hodgkin’s Lymphoma (NHL) US Market Size (USD Millions), (2011-2014)
• Table 10: Non-Hodgkin’s Lymphoma (NHL) US Market Size (USD Millions), (2015-2020)
• Table 11: Non-Hodgkin’s Lymphoma (NHL) United Kingdom Market Size (USD Millions), (2011-2014)
• Table 12: Non-Hodgkin’s Lymphoma (NHL) Germany Market Size (USD Millions), (2015-2020)
• Table 13: Non-Hodgkin’s Lymphoma (NHL) United Kingdom Market Size (USD Millions), (2011-2014)
• Table 14: Non-Hodgkin’s Lymphoma (NHL) United Kingdom Market Size (USD Millions), (2015-2020)
• Table 15: Non-Hodgkin’s Lymphoma (NHL) France Market Size (USD Millions), (2011-2014)
• Table 16: Non-Hodgkin’s Lymphoma (NHL) France Market Size (USD Millions), (2015-2020)
• Table 17: Non-Hodgkin’s Lymphoma (NHL) Italy Market Size (USD Millions), (2011-2014)
• Table 18: Non-Hodgkin’s Lymphoma (NHL) Italy Market Size (USD Millions), (2015-2020)
• Table 19: Non-Hodgkin’s Lymphoma (NHL) Spain Market Size (USD Millions), (2011-2014)
• Table 20: Non-Hodgkin’s Lymphoma (NHL) Spain Market Size (USD Millions), (2015-2020)
• Table 21: Non-Hodgkin’s Lymphoma (NHL) Japan Market Size (USD Millions), (2011-2014)
• Table 22: Non-Hodgkin’s Lymphoma (NHL) Japan Market Size (USD Millions), (2015-2020)
• Table 23: Non-Hodgkin’s Lymphoma (NHL) ROW Market Size (USD Millions), (2011-2014)
• Table 24: Non-Hodgkin’s Lymphoma (NHL) ROW Market Size (USD Millions), (2015-2020)
List of Figures
• Figure 1: Non-Hodgkin’s Lymphoma (NHL) Drug Sales (USD Millions), (2011-2014)
• Figure 2: Global Epidemiology of Non-Hodgkin’s Lymphoma (NHL) (2011-2020)
• Figure 3: Non-Hodgkin’s Lymphoma (NHL) Global Market Size (USD Millions), (2011-2014)
• Figure 4: Non-Hodgkin’s Lymphoma (NHL) Global Market Size (USD Millions), (2015-2020)
• Figure 5: Non-Hodgkin’s Lymphoma (NHL) US Market Size (USD Millions), (2011-2014)
• Figure 6: Non-Hodgkin’s Lymphoma (NHL) US Market Size (USD Millions), (2015-2020)
• Figure 7: Non-Hodgkin’s Lymphoma (NHL) Germany Market Size (USD Millions), (2011-2014)
• Figure 8: Non-Hodgkin’s Lymphoma (NHL) Germany Market Size (USD Millions), (2015-2020)
• Figure 9: Non-Hodgkin’s Lymphoma (NHL) United Kingdom Market Size (USD Millions), (2011-2014)
• Figure 10: Non-Hodgkin’s Lymphoma (NHL) United Kingdom Market Size (USD Millions), (2015-2020)
• Figure 11: Non-Hodgkin’s Lymphoma (NHL) France Market Size (USD Millions), (2011-2014)
• Figure 12: Non-Hodgkin’s Lymphoma (NHL) France Market Size (USD Millions), (2015-2020)
• Figure 13: Non-Hodgkin’s Lymphoma (NHL) Italy Market Size (USD Millions), (2011-2014)
• Figure 14: Non-Hodgkin’s Lymphoma (NHL) Italy Market Size (USD Millions), (2015-2020)
• Figure 15: Non-Hodgkin’s Lymphoma (NHL) Spain Market Size (USD Millions), (2011-2014)
• Figure 16: Non-Hodgkin’s Lymphoma (NHL) Spain Market Size (USD Millions), (2015-2020)
• Figure 17: Non-Hodgkin’s Lymphoma (NHL) Japan Market Size (USD Millions), (2011-2014)
• Figure 18: Non-Hodgkin’s Lymphoma (NHL) Japan Market Size (USD Millions), (2015-2020)
• Figure 19: Non-Hodgkin’s Lymphoma (NHL) ROW Market Size (USD Millions), (2011-2014)
• Figure 20: Non-Hodgkin’s Lymphoma (NHL) ROW Market Size (USD Millions), (2015-2020)
